Most people searching for uterine cancer symptoms are really asking one question: is this bleeding something to worry about? One symptom matters above all others. Vaginal bleeding after menopause is never normal, and it should always be evaluated. The reassuring half of that sentence counts just as much: the great majority of postmenopausal bleeding has a harmless cause. But because bleeding appears early, uterine cancer is caught at an early stage more often than most cancers, and early-stage disease is usually curable with surgery alone.
In this article you will learn which signs matter and which do not, why there is no screening test for this disease, what a work-up for abnormal bleeding involves, and how a newer way of classifying these tumors is changing treatment.
What uterine cancer is, and the two main types
The uterus has two very different tissue layers, and cancer can start in either one. That distinction drives how the disease behaves and how it is treated.
Endometrial carcinoma
Around nineteen out of twenty uterine cancers begin in the endometrium, the lining that thickens and sheds during a menstrual cycle. These are endometrial carcinomas, and in everyday conversation “uterine cancer” almost always means this. It is the most common gynecologic cancer in the United States, and its incidence is rising rather than falling.
Uterine sarcoma
A small minority of uterine cancers start in the muscular wall or connective tissue rather than the lining. These uterine sarcomas are rare, grow faster, and are less likely to announce themselves with the classic bleeding pattern; a rapidly enlarging fibroid-like mass or pelvic pressure worsening over weeks can be the clue. This article focuses on endometrial carcinoma, which is what nearly every person with abnormal bleeding is evaluated for.
Type 1 and type 2 endometrial carcinoma
Endometrial carcinomas are traditionally sorted into two behavioral groups. This is not a formal staging system, but it explains why two people with the same diagnosis can receive very different advice.
| Feature | Type 1 | Type 2 |
|---|---|---|
| How common | The clear majority of cases | A minority of cases |
| Main driver | Estrogen unbalanced by progesterone | Largely independent of hormones |
| Typical tissue type | Endometrioid, usually low grade | Serous, clear cell, carcinosarcoma |
| Usual body type at diagnosis | Often excess weight, insulin resistance | Often in leaner, older patients |
| Usual outlook | Usually caught early, generally favorable | More likely to spread; needs intensive care |
Uterine cancer symptoms you should never ignore
Nearly everyone diagnosed with endometrial cancer has some form of abnormal bleeding, and for most it is the only symptom. This is the single most useful thing to know about the disease.
Bleeding after menopause
Once you have gone twelve months without a period, any vaginal bleeding is abnormal: spotting, a pink or brown discharge, a single episode that stops on its own, bleeding you assume came from irritation. The CDC is unambiguous that bleeding after menopause is never normal and should be checked promptly. Most of the time the explanation is benign: a thinned lining, a polyp, or an effect of hormone therapy. But only an evaluation separates those from cancer, and that evaluation is quick.
Changes before menopause
Before menopause the signal is noisier, because irregular cycles are common in the perimenopausal years. Patterns worth raising include bleeding between periods, periods much heavier or longer than your own baseline, cycles arriving less than three weeks apart, and bleeding after sex. Age matters less than change: a new, persistent departure from your usual pattern is what to report, even in your thirties. If you are unsure where you are in the transition, it helps to read a plain-language guide to menopause stages and symptoms.
Discharge, pain and later signs
A watery, blood-tinged or foul-smelling discharge without obvious bleeding can occasionally be the first sign, particularly in older patients. Pelvic pain, pain during sex, and unexplained weight loss tend to appear later rather than first. Persistent bloating, early fullness after eating and a change in bowel habit point to a different diagnosis, and readers who recognize that pattern should review the early warning signs of ovarian cancer instead. Bleeding after sex with an otherwise normal cycle points toward the cervix, a pattern covered in a separate guide to cervical cancer symptoms and causes.
When to see a doctor
- Any bleeding or spotting after menopause, however light or brief, warrants an appointment within days rather than months.
- Bleeding between periods, or periods far heavier than your normal, continuing beyond two or three cycles.
- A new watery or blood-streaked discharge that does not settle.
- Pelvic pain or pressure that is new, persistent, and not tied to your cycle.
- Any of the above if you take tamoxifen or estrogen without progesterone, or have Lynch syndrome in the family.
Long or heavy bleeding also drains iron, so fatigue, breathlessness on stairs or unusual pallor are worth mentioning. Clinicians frequently order a complete blood count here, and a low result may indicate iron deficiency anemia from chronic blood loss.
What causes uterine cancer and who is most at risk
Most endometrial cancers trace back to one theme: the lining has been stimulated by estrogen for years without enough progesterone to balance it. Progesterone tells the endometrium to stop growing and shed. Without that brake, cells divide more often, and more division means more chances for a DNA error.
The estrogen connection
Several common situations create that imbalance. Carrying excess body fat is the largest modifiable contributor, because fat tissue converts adrenal hormones into estrogen, and after menopause that becomes the body’s main estrogen source. Estrogen therapy without a progestin in someone who still has a uterus does the same directly. Polycystic ovary syndrome causes cycles without ovulation, and no ovulation means no progesterone. Early periods, late menopause, and never having been pregnant all extend the lining’s total exposure. Readers who want the hormonal background can review what an estradiol blood test measures.
Medical conditions and medications
Type 2 diabetes and insulin resistance are independently associated with higher risk, partly through hormones and partly through the growth-promoting effects of chronically high insulin, which is one reason clinicians watch what a fasting insulin result reveals about metabolic health. Tamoxifen blocks estrogen in breast tissue but mildly stimulates the endometrium, raising risk in postmenopausal users; this is a known, managed trade-off rather than a reason to stop treatment, and bleeding on tamoxifen should be reported quickly. Endometrial hyperplasia, particularly the atypical form, is a precancerous overgrowth that can be treated before it becomes cancer.
Inherited risk and Lynch syndrome
A small share of endometrial cancers arise in people with Lynch syndrome, an inherited condition affecting the DNA mismatch repair genes that proofread copying errors. For many women with Lynch syndrome, endometrial cancer is the first cancer they develop, often before any bowel cancer and at a younger age. That is why tumors are now routinely tested for mismatch repair proteins, and why an abnormal result triggers a genetics referral for the patient and potentially relatives. The same syndrome underlies a share of bowel tumors, covered in a companion guide to colorectal cancer risk and treatment. Pelvic pain alone is a different question, addressed in an overview of endometriosis symptoms and management.
Why there is no screening test for uterine cancer
This surprises many people, so it is worth stating plainly: there is no recommended screening test for uterine cancer in the general population. No organization advises routine ultrasound, biopsy or blood testing for women without symptoms.
A Pap test is not a uterine cancer test. It samples cells from the cervix and is designed to find cervical precancer. It occasionally picks up abnormal endometrial cells by accident, and that finding is taken seriously, but a normal Pap result tells you nothing reassuring about the uterus itself. This is the most common misconception about the disease.
No blood test diagnoses uterine cancer either. CA-125 is sometimes measured, but its role is limited to advanced or high-grade disease, where it helps gauge spread and follow treatment response. It is frequently normal in early cancer and rises in plenty of benign conditions. Anyone who has had one ordered can read what a CA-125 result actually means. Screening is absent not through neglect: the disease announces itself with bleeding early enough to act on, and testing everyone would produce far more false alarms than benefit.
The exception is people with Lynch syndrome or another strong inherited risk, who may be offered surveillance and, once childbearing is complete, a risk-reducing hysterectomy. Those decisions are made with a genetics team.
How doctors investigate abnormal bleeding
The work-up is standardized, fast and mostly done in the clinic. Knowing the sequence removes much of the anxiety.
Step one: transvaginal ultrasound
A slim probe placed in the vagina measures the thickness of the endometrium. In a postmenopausal woman with bleeding, a thin lining makes cancer very unlikely and often ends the work-up there. A thickened lining does not mean cancer; it means the next step is needed. Ultrasound is a filter, not a verdict.
Step two: endometrial biopsy
A narrow flexible tube passed through the cervix draws a small sample of the lining. It takes a couple of minutes in an office visit, feels like a strong cramp, and gives the definitive answer in most cases. The pathologist uses this sample to determine whether cancer is present and, increasingly, which molecular group it belongs to.
Step three: hysteroscopy and dilation and curettage
If the biopsy is inconclusive, yields too little tissue, or bleeding continues despite a reassuring result, a hysteroscopy is done. A thin camera lets the surgeon see the cavity directly and take targeted samples, usually with a curettage that scrapes a fuller specimen. Persistent bleeding after a normal biopsy should always be re-investigated.
What the lab work adds
Blood tests do not diagnose this cancer, but they support the work-up. A blood count shows whether the bleeding has caused anemia, and what a hemoglobin measurement reflects is often the first number checked. Kidney, liver and clotting results are needed before surgery. Where testing genuinely changes the path is mismatch repair status, which feeds into both the genetic counseling conversation and the treatment plan below.
The molecular classification that now changes treatment
Until recently, treatment decisions after surgery rested on how the tumor looked under a microscope and how far it had spread. Pathologists now also sort endometrial cancers into four molecular groups, and this has genuinely altered practice rather than added a label.
| Molecular group | What it means | Effect on treatment |
|---|---|---|
| POLE-mutated | A fault in a DNA-copying enzyme; the tumor carries huge numbers of mutations | Excellent outlook; supports less treatment after surgery |
| Mismatch repair deficient | The DNA proofreading system has failed, sometimes because of Lynch syndrome | Triggers genetic referral; predicts benefit from immunotherapy |
| p53-abnormal | A key tumor-suppressor gene is faulty; behaves aggressively even when small | Supports more intensive treatment, often chemotherapy |
| No specific molecular profile | None of the above; the largest, most varied group | Decisions rest mainly on stage, grade and tissue features |
The consequence is that two tumors that look identical under a microscope can now lead to opposite recommendations. A POLE-mutated tumor may let a patient safely avoid radiation or chemotherapy she would once have received, while a p53-abnormal tumor at the same stage may prompt treatment she would once have been spared.
How uterine cancer is treated
Surgery is the mainstay
For most people, treatment is surgery: removal of the uterus and cervix, usually with the ovaries and fallopian tubes, commonly through small incisions or robotically. Sentinel lymph node mapping, in which a dye identifies the first node the tumor would drain into so only that node is removed, has largely replaced wholesale removal of pelvic nodes and spares many people long-term leg swelling. For disease confined to the uterus, surgery alone is often the entire treatment.
Treatment after surgery
Whether anything is added depends on stage, grade, depth of invasion, whether cancer cells appear in small vessels, and now the molecular group. Options include vaginal brachytherapy, a short internal radiation aimed at the top of the vagina where recurrence is most likely, external beam radiation, chemotherapy, or a combination. Many patients with early low-grade disease need nothing further.
Immunotherapy for advanced mismatch repair deficient disease
For cancer that has spread or come back, adding an immune checkpoint inhibitor to standard chemotherapy has become a new standard of care, and the benefit is largest in tumors with a mismatch repair defect. These drugs release a brake on immune cells, and a mismatch repair defect leaves the tumor covered in abnormal proteins the immune system can recognize.
Hormone therapy and fertility-sparing care
Progestin treatment, given as tablets or through a hormone-releasing intrauterine device, can shrink low-grade, hormone-sensitive tumors. In carefully selected younger patients with atypical hyperplasia or a low-grade cancer confined to the lining, this makes it possible to postpone hysterectomy and attempt pregnancy. The conditions are strict: expert pathology review, imaging showing no invasion into the muscle wall, repeat sampling every few months, and an agreement to proceed to surgery once childbearing is complete or if the cancer does not respond. It suits a small, well-defined group rather than serving as an alternative to surgery. Hormone testing plays a supporting role, including what a progesterone level indicates about ovulation.
Latest scientific advances
Research over the past three years has changed real decisions in the clinic.
Immunotherapy added to chemotherapy for advanced disease
Two large international trials published in 2023 tested adding an immune checkpoint drug, either dostarlimab or pembrolizumab, to standard chemotherapy in advanced or recurrent endometrial cancer. Both found the combination kept the cancer under control for substantially longer than chemotherapy alone, and the effect was dramatic in mismatch repair deficient tumors — the DNA proofreading system was broken, making the tumor easier for the immune system to spot. A 2025 follow-up reported longer-term survival data still favoring the combination, though those figures are maturing. What this means for you: if you or a relative is diagnosed with advanced or recurrent uterine cancer, ask whether the tumor has been tested for mismatch repair status, because that one result determines whether immunotherapy is likely to help.
Molecular classification can now be done on the first biopsy
A 2025 study compared molecular test results from the initial office biopsy with results from the uterus removed at surgery in the same patients, and found the two agreed almost all of the time. What this means for you: the molecular group can often be known before surgery rather than weeks after, so the plan can be discussed at the first consultation. This was a single-center study needing confirmation, but it points toward earlier, better-informed conversations.
Fertility-sparing treatment: real, but the evidence is still thin
A 2025 Cochrane review — Cochrane reviews pool all the trials on a question and grade how trustworthy the answer is — examined hormone treatment used instead of hysterectomy in younger patients with atypical hyperplasia or very early cancer. Adding metformin to a progestin may slightly improve the chance the lining returns to normal, and a hormone-releasing intrauterine device works about as well as tablets with fewer side effects. The reviewers rated the certainty as low, and no study reported long-term survival. What this means for you: fertility-sparing treatment is a legitimate option worth raising with a gynecologic oncologist, but as a carefully monitored path with genuine uncertainty rather than a substitute for surgery.
Where ultrasound thresholds still fall short
A 2024 systematic review asked what endometrial thickness should prompt further testing in postmenopausal women who are not bleeding — when a thickened lining is spotted on a scan done for another reason. Pooling sixteen studies, the authors concluded that no reliable threshold could be established from existing evidence. What this means for you: the well-established ultrasound cut-off applies to postmenopausal women who are bleeding. If a thickened lining is found by chance without bleeding, no single number settles it, and the decision to biopsy should be individualized with your clinician.
Glossary
| Term | Definition |
|---|---|
| Endometrium | The inner lining of the uterus, which thickens and sheds during a menstrual cycle. Almost all uterine cancers start here. |
| Endometrial hyperplasia | An overgrowth of the uterine lining. The atypical form is precancerous and can usually be treated before cancer develops. |
| Transvaginal ultrasound | A scan using a slim probe placed in the vagina, which measures the thickness of the uterine lining. |
| Endometrial biopsy | An office procedure in which a thin tube collects a small sample of the lining for a pathologist to examine. |
| Hysteroscopy | A procedure using a thin camera passed through the cervix to view the inside of the uterus and take targeted samples. |
| Mismatch repair (MMR) | The cell’s system for correcting copying errors in DNA. When it fails, mutations accumulate and tumors become easier for the immune system to recognize. |
| Lynch syndrome | An inherited condition affecting mismatch repair genes that raises the lifetime risk of uterine, bowel and other cancers. |
| POLE mutation | A change in a DNA-copying enzyme that produces very heavily mutated tumors which, unexpectedly, have an excellent outlook. |
| p53 | A tumor-suppressor gene that normally halts damaged cells. Tumors with abnormal p53 behave more aggressively. |
| Sentinel lymph node | The first lymph node a tumor would drain into. Removing and examining only this node avoids the side effects of taking many nodes. |
Frequently asked questions
How did most people first notice they had uterine cancer?
In the large majority of cases, the first thing noticed was bleeding that did not fit the usual pattern: spotting after menopause, a period that suddenly became much heavier, or bleeding between periods. Many people describe it as easy to dismiss at first, a small amount of pink or brown discharge rather than a real bleed. That is exactly why it is worth reporting. Pain, bloating and weight loss are usually late features rather than first signs, so waiting for those before making an appointment misses the window in which the disease is most treatable.
Can you get uterine cancer in your thirties or forties?
Yes, though it is much less common. Estimates place somewhere between one in seven and one in four diagnoses before menopause. Risk is higher in younger people with polycystic ovary syndrome, significant excess weight, cycles that are frequently anovulatory, or Lynch syndrome in the family. The practical message is the same at any age: persistent bleeding between periods, or a lasting change from your own normal pattern, should be evaluated rather than attributed to stress or hormones by default.
What does a thickened uterine lining on ultrasound mean?
It means further testing is warranted, not that cancer has been found. A thickened endometrium can reflect a polyp, a benign overgrowth, hormone therapy, or simply normal variation. In a postmenopausal woman who is bleeding, a thickened lining leads to a biopsy. If the lining is found to be thickened by chance in someone with no bleeding at all, the evidence on what threshold should prompt a biopsy is genuinely unsettled, and the decision is individualized.
What is the survival rate for uterine cancer?
Survival depends heavily on stage and tumor type, so an overall figure can mislead. What is consistent is that most uterine cancers are found while still confined to the uterus, because bleeding brings people in early, and outcomes at that stage are among the best of any cancer. Disease that has spread beyond the uterus, or a high-grade or p53-abnormal tumor, carries a poorer outlook and needs more intensive treatment. Your own care team can give figures that reflect your actual stage and molecular group rather than a population average.
Does a hysterectomy mean the cancer cannot come back?
Removing the uterus removes the cancer’s origin, and for early-stage disease it is often curative on its own. Recurrence is still possible, most commonly at the top of the vagina or in nearby lymph nodes, which is why some people are offered radiation or chemotherapy afterward and why follow-up visits continue for several years. The chance of recurrence is much lower for early low-grade disease than for high-grade or p53-abnormal tumors, and your molecular group is part of how that risk is estimated.
Does having a Pap test protect me from uterine cancer?
No. A Pap test samples the cervix and is designed to detect cervical precancer. It is not a test of the uterine lining, and a normal Pap result does not rule out uterine cancer. Occasionally a Pap picks up abnormal endometrial cells by chance and that finding is investigated, but this is incidental rather than the test’s purpose. Keep up with cervical screening for what it does do, and treat abnormal bleeding as a separate issue that needs its own evaluation.
Sources
- Centers for Disease Control and Prevention — Symptoms of Uterine Cancer, 2025 — cdc.gov
- MedlinePlus, National Library of Medicine — Uterine Cancer, 2025 — medlineplus.gov
- Mayo Clinic — Endometrial cancer: symptoms and causes, 2025 — mayoclinic.org
- Mirza MR et al. — Dostarlimab for primary advanced or recurrent endometrial cancer — New England Journal of Medicine, 2023 — doi.org/10.1056/NEJMoa2216334
- Eskander RN et al. — Pembrolizumab plus chemotherapy in advanced endometrial cancer — New England Journal of Medicine, 2023 — doi.org/10.1056/NEJMoa2302312
- Eskander RN et al. — Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial — Nature Medicine, 2025 — doi.org/10.1038/s41591-025-03566-1
- Nozaki T et al. — Preoperative molecular classification of endometrial cancer: validation through biopsy and matched hysterectomy specimens — Gynecologic Oncology, 2025 — doi.org/10.1016/j.ygyno.2025.10.026
- Fernandez-Montoli ME et al. — Fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer — Cochrane Database of Systematic Reviews, 2025 — doi.org/10.1002/14651858.CD013111.pub2
- Kaur H et al. — The optimal endometrial thickness threshold for prediction of endometrial cancer in postmenopausal women without bleeding remains uncertain: systematic review and meta-analysis — Journal of Gynecology Obstetrics and Human Reproduction, 2024 — doi.org/10.1016/j.jogoh.2024.102831
Further reading
- Anyone taking tamoxifen may want to review a guide to breast cancer symptoms and treatments.
- Metabolic risk overlaps considerably here, and readers can explore the causes and management of diabetes.
- To track blood sugar over months rather than moments, learn how to read a glycated hemoglobin result.
- Cycle irregularities often prompt hormone testing, so it helps to understand what follicle-stimulating hormone levels indicate.
- People navigating unexplained pelvic symptoms can compare the meaning of a CA-125 test result.
Understand your lab results with BloodSense
A work-up for abnormal bleeding produces a stack of numbers that rarely get explained: a blood count showing whether you have become anemic, iron studies, hormone levels, kidney and liver panels taken before surgery, and sometimes a CA-125. None of these diagnose uterine cancer, but understanding them helps you follow your own care and ask sharper questions at your next appointment. BloodSense reads your report and explains each marker in plain language, in minutes. It helps you understand your results; it does not diagnose, and it does not replace your doctor.
